Please login to the form below

Not currently logged in
Email:
Password:

GSK agrees Rwanda access to generic HIV drugs

UK-based GlaxoSmithKline (GSK) has given consent through Canada's Access to Medicines Regime to enable local pharmaceutical firm Apotex to manufacture a generic fixed dose combination antiretroviral, containing GSK's patented active ingredients zidovudine and lamivudine for the treatment of HIV/AIDS in Rwanda.

UK-based GlaxoSmithKline (GSK) has given consent through Canada's Access to Medicines Regime to enable local pharmaceutical firm Apotex to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing GSK's patented active ingredients zidovudine and lamivudine for the treatment of HIV/AIDS in Rwanda.

Canada's Access to Medicines Regime allows the government to authorise the production of certain patented medicines for export. The legislation includes controls which are designed to ensure that these essential medicines reach the patients for whom they are intended and the authorisation to be granted will be subject to these controls.

GSK has agreed to waive royalties as long as Apotex's triple combination generic anti-retroviral will be supplied on a strictly not-for-profit basis.

CEO for GSK Canada, Paul Lucas, said: "Tackling the AIDS crisis is one of the greatest challenges the world faces. GSK continues to play its part to tackle this crisis through research and development, not-for-profit pricing and ongoing investment in dedicated community programmes. Our decision to allow Apotex to manufacture an FDC containing two GSK molecules is part of this broad commitment."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....